Novel DNA aptamers and their uses

Through Cell-SELEX technology, DNA aptamers are selected and modified, and the early diagnosis and treatment of pancreatic cancer is solved, and efficient diagnosis and treatment of pancreatic cancer and other cancers are achieved, providing a new type of DNA with specific binding and high serum stability is provided. aptamer.

CN113646442BActive Publication Date: 2024-12-03NATIONAL CANCER CENTER(JP) +1
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN201980092801.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-12-21
Filing Date
2019-08-08
Publication Date
2024-12-03
Estimated Expiration
2039-08-08

AI Technical Summary

Technical Problem

The prior art is difficult to diagnose and treat pancreatic cancer early, especially due to the lack of suitable early detection markers and effective anti-cancer agents, which leads to difficulty in early detection of pancreatic cancer and poor treatment effect.

Method used

Using Cell-SELEX technology to select DNA aptamers that specifically bind to the pancreatic cancer cell membrane from pancreatic cancer cells, and through modification, it has developed a novel DNA aptamers that can specifically bind to cancer cells. body.

Benefits of technology

It has achieved efficient diagnosis and treatment of pancreatic cancer and other types of cancer, and enhanced the binding affinity for cancer cells by improving the targeting efficiency and serum stability of DNA aptamers, providing new diagnostic and therapeutic means.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113646442B_ABST
    Figure CN113646442B_ABST
Patent Text Reader

Abstract

This disclosure relates to novel DNA aptamers and their uses. Specifically, this disclosure relates to the selection of DNA aptamers from a DNA library using Cell-SELEX that specifically bind to cancer cells. The DNA aptamers selected and optimized in this disclosure exhibit high binding affinity to cancer cells and, due to their enhanced targeting efficiency to target cells and tissues and high serum stability, can be effectively used for cancer diagnosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to novel DNA aptamers. Specifically, the present disclosure relates to using Cell-SELEX to select DNA aptamers that specifically bind to cancer cells from a cancer DNA library. The present disclosure also relates to compositions comprising novel DNA aptamers that target cancer tissues, diagnose cancer, or treat cancer. The present disclosure is based on original research projects of the National Cancer Center (NCC) and research conducted as part of the TIPS program (TechIncubator Program for Startup) from the Ministry of Small and Medium Enterprises and Startups.

[0002] [Project No.: NCC-1210080, Title: Identification of pancreatic cancer-specific metastasis factors using Cell-SELEX]

[0003] [Project No.: NCC-1410270, Title: Development of novel anticancer drugs by establishing an aptamer-antibody coupling platform]

[0004] [Project number: S2562351, Title: Development of pancreatic cancer therapeutics using aptamer-antibody-drug conjugates] Background Art

[0005] Aptamers are single-stranded DNA or RNA oligonucleotides with unique three-dimensional structures that specifically bind to target molecules in a manner similar to antibodies. Generally speaking, aptamers have high affinity at concentrations as low as nanomolar (nmol) to picomolar (pmol).

[0006] Aptamers are often compared to antibodies because both have target-specific binding properties. Compared to antibodies, aptamers are easy to produce by chemical synthesis without the use of biological processes in cells or animals, are relatively stable at high temperatures, and have advantages in proximity to targets due to their small size. In addition, aptamers are superior to antibodies in their potential as therapeutic agents because they are easy to modify during chemical synthesis and are non-immunogenic and non-toxic. However, a disadvantage of aptamers is their short half-life because they are easily degraded by nucleases in the body. This disadvantage can be overcome by various chemical modifications.

[0007] Cancer needs to be detected and treated at an early stage. Specifically, pancreatic cancer is a cancer with the worst prognosis, with the highest 1-year mortality rate of all cancers. The 2-year survival rate for pancreatic cancer is approximately 10%, and the 5-year survival rate is only 8% or less. Over the past two decades, the 5-year survival rate for almost all cancers has increased substantially, but the outcome for pancreatic cancer is very poor, rising from a reported 3% in 1997 to only about 8% in 2016.

[0008] In reality, only about 20% of pancreatic cancer patients are considered operable, and even in this case, the survival rate after surgery may be as high as 90% or higher only when the tumor size is 1 cm or less and there is no lymph node metastasis or distant metastasis. However, most patients are already inoperable at the time of diagnosis. When the tumor is inoperable, patients usually rely on chemotherapy or radiotherapy. However, since there is currently no clear standardized treatment, early detection of pancreatic cancer is very important to improve survival rates.

[0009] Pancreatic cancer has almost no early symptoms, and by the time patients realize the symptoms, in most cases, the cancer has already developed to the late stage. Therefore, early diagnosis of pancreatic cancer is very difficult. Currently, there are almost no early detection markers applicable to pancreatic cancer in practice.

[0010] Early pancreatic cancer is usually defined as a tumor less than 2 cm in size and confined to the pancreas without invasion or lymph node metastasis. However, even when the size of pancreatic cancer is less than 2 cm (the threshold for early pancreatic cancer), metastasis is found in up to 50% of such cases. Even in stage II (classified as early pancreatic cancer when pancreatic cancer is staged based on tumor size, lymph node metastasis, and distant metastasis), invasion is common in areas connected to the superior mesenteric vein or portal vein, as well as early metastasis of a few cells. In this case, the tumor is unresectable. In cases where surgery is performed on the tumor considering that no distant metastasis is found on scans and the tumor is determined to be confined to the pancreas, it is not uncommon to find distant metastasis soon after surgery. In this case, even with surgery, the risk of recurrence is high, and the median survival is only 6 to 12 months due to the lack of effective anticancer agents. In view of the above, it is necessary to detect early pancreatic cancer that has not yet developed substantial distant metastasis or early metastasis of a few cells, at least for the purpose of early surgical resection (the only curative treatment for pancreatic cancer).

[0011] When developing probes targeting cell surface proteins, the extracellular domains of cell surface proteins can be isolated and purified in the form of recombinant proteins and then used as antigens to develop antibodies or select aptamers. The screening process for selecting aptamers is usually called SELEX (systematic evolution of ligands by exponential enrichment) technology. This technology usually uses isolated recombinant proteins. However, during the separation process, the three-dimensional structure of the cell surface protein may change, which may cause the selected aptamer to actually fail to bind to the target protein on the cell surface if the three-dimensional structure of the protein is crucial for binding to the target protein.

[0012] Such limitations can be overcome by using the Cell-SELEX method, which, unlike the traditional SELEX technique, involves the use of living cells to specifically select aptamer cell membranes.

[0013] In the present disclosure, the Cell-SELEX method is used to select DNA aptamers with high binding affinity to pancreatic cancer on pancreatic cancer cells, and then the selected aptamers are further studied to improve the targeting efficiency of cells and tissues and serum stability. It has been found that the selected aptamers can specifically bind to pancreatic cancer as well as various cancers such as colon cancer, liver cancer, lung cancer, brain tumor, oral cancer, ovarian cancer and breast cancer.

[0014] [Prior art literature]

[0015] (Patent Document 1) KR 10-1458947

[0016] (Patent Document 2) KR 10-1250557

[0017] Brief description of the invention

[0018] One object of the present disclosure is to provide novel DNA aptamers. Specifically, the novel DNA aptamers are DNA aptamers that exhibit cancer-specific binding.

[0019] Another object of the present disclosure is to provide a method for diagnosing or treating cancer using a DNA aptamer that exhibits cancer-specific binding.

[0020] The purpose of the present disclosure is to develop an aptamer that can detect cancer cells. Cell-SELEX technology was used to select aptamers that specifically bind to pancreatic cancer cell membranes. Specifically, in the present disclosure, CMLu-1 cells isolated from metastatic pancreatic cancer tissue were used as target cells and normal pancreatic tissue cells HPNE were used as controls to select aptamers that specifically bind to pancreatic cancer cells.

[0021] In one aspect, the present disclosure provides a DNA aptamer comprising a nucleotide sequence as shown in SEQ ID NO:6. In another aspect, the present disclosure provides a DNA aptamer comprising a nucleotide sequence having at least 90% or 95% homology to the nucleotide sequence as shown in SEQ ID NO:6. In one aspect of the present disclosure, the DNA aptamer may exhibit specific binding to cancer. In one aspect of the present disclosure, the DNA aptamer may consist of a nucleotide sequence as shown in SEQ ID NO:6.

[0022] In another aspect, the present disclosure provides a DNA aptamer consisting of a nucleotide sequence having at least 90% or 95% homology to the nucleotide sequence shown in SEQ ID NO: 4. In one aspect of the present disclosure, the DNA aptamer may consist of a nucleotide sequence shown in SEQ ID NO: 4.

[0023] As used herein, "a nucleotide sequence having at least 90% homology" refers to a nucleotide sequence comprising one or more nucleotide additions, deletions or substitutions to have a nucleotide sequence identity of greater than or equal to 90% but less than 100% with a reference sequence, and exhibits similar cancer-specific binding.

[0024] In one aspect of the present disclosure, a nucleotide sequence having at least 90% homology to SEQ ID NO:4 may refer to a nucleotide sequence that differs from SEQ ID NO:4 in a region of SEQ ID NO:4, but not in a region corresponding to the nucleotide sequence of SEQ ID NO:6.

[0025] The term "DNA aptamer" as used herein refers to a short single-stranded oligonucleotide that binds to a corresponding target with high affinity and specificity and has a unique three-dimensional structure. Through repeated in vitro selection and enrichment processes, DNA molecules that specifically bind to a specific target, i.e., DNA aptamers, can be selected from a DNA aptamer library.

[0026] In an experimental example of the present disclosure, aptamers of a DNA pool enriched by the Cell-SELEX process were clustered into 11 aptamer families (SQ1 to SQ11) based on their sequence similarity. Among these families, SQ7 has been identified as having high binding affinity to pancreatic cancer-derived metastatic cancer cells CMLu-1, and the aptamers in the SQ7 family have high sequence homology with each other, with only some nucleotide differences (SQ7a and SQ7b aptamers in Table 3).

[0027] In addition, using the SQ7 (SEQ ID NO: 4) aptamer (80-mer) that specifically binds to pancreatic cancer tissue-derived cells as a template, a truncated aptamer (32-mer) was prepared to increase the synthesis yield and reduce the synthesis cost. Specifically, the SQ7-1 aptamer (SEQ ID NO: 6) was prepared, which reduced the size of the aptamer by more than half while maintaining the binding affinity to the CMLu-1 target cells. The inventors of the present disclosure concluded that the SQ7-1 aptamer is a region of the SQ7 aptamer sequence that is critical to its ability to target cancer cells and cancer tissues, and further experiments were conducted based on this.

[0028] In one aspect of the present disclosure, a modified DNA aptamer is provided, wherein the modification has been introduced into the DNA aptamer of the present disclosure to make it resistant to DNA enzymes, and the modification is present in at least 10% of the nucleotides of SEQ ID NO: 6. In addition, the modified DNA aptamer has a nucleotide sequence as shown in SEQ ID NO: 8, 12 or 14.

[0029] In one aspect of the present disclosure, the modification introduced to confer DNA enzyme resistance can be replacing the -OH group on the 2' carbon of the sugar group in one or more nucleotides with -Me (methyl), -OMe, -NH2, -F (fluorine), -O-2-methoxyethyl-O-propyl, -O-2-methylthioethyl, -O-3-aminopropyl, -O-3-dimethylaminopropyl, -ON-methylacetamido or -O-dimethylamidooxyethyl.

[0030] In a working example of the present disclosure, based on the SQ7-1 aptamer as a template, internal 2'-O-methyl modified aptamers were prepared by modifying different regions in the secondary structure of the SQ7-1 aptamer, and the serum half-life of the modified aptamers was measured to study their serum stability. The results showed that compared with the SQ7-1 aptamer, the serum half-life of some modified aptamers increased by 90 times or more.

[0031] The target cells used for Cell-SELEX in the working examples of the present disclosure are CMLu-1 cells, which are obtained from metastatic pancreatic cancer tissues by orthotopic transplantation experiments. Therefore, the present disclosure may be particularly applicable to the diagnosis of pancreatic cancer.

[0032] The present disclosure provides a composition targeting cancer tissue, which comprises the above-mentioned DNA aptamer. In one aspect of the present disclosure, in addition to the above-mentioned ingredients, the composition comprising the DNA aptamer may also comprise an active ingredient having the same or similar function, or a stable composition formula, or an ingredient that enhances the stability of the aptamer. In one aspect of the present disclosure, the composition may be a pharmaceutical composition.

[0033] In addition, the present disclosure provides a composition for diagnosing cancer, comprising the aptamer as described in one aspect of the present disclosure.

[0034] In one aspect of the disclosure, DNA aptamers can be used in combination with effector moieties.

[0035] In one aspect of the disclosure, the effector moiety can be a cytotoxic agent, an immunosuppressant, an imaging agent (eg, a fluorescent moiety or a chelator), a nanomaterial, or a toxin polypeptide. The cytotoxic agent can be a chemotherapeutic agent.

[0036] In one aspect, the present disclosure relates to a composition for treating cancer, which comprises the novel DNA aptamer as described in one aspect of the present disclosure and an anticancer agent coupled to the DNA aptamer.

[0037] In one aspect of the present disclosure, the cancer may be, but is not limited to, pancreatic cancer, colon cancer, liver cancer, lung cancer, brain tumor, oral cancer, ovarian cancer, or breast cancer.

[0038] In one aspect of the present disclosure, the anticancer agent may be selected from but not limited to MMAE (monomethyl auristatin E), MMAF (monomethyl auristatin F), calicheamicin, mertansine (DM1), ravtansine (DM4), tesirine (SCX), doxorubicin, cisplatin, SN-38, duocarmycin and pyrrolobenzodiazepine (PBD) The group consisting of one or more.

[0039] In one aspect of the present disclosure, the DNA aptamer can be coupled to polyethylene glycol (PEG) or its derivatives, diacylglycerol (DAG) or its derivatives, antibodies, dendrimers, or zwitterion-containing biocompatible polymers (eg, phosphorylcholine-containing polymers).

[0040] In one aspect of the present disclosure, the composition may further contain a physiologically acceptable excipient, carrier or additive, which may include but is not limited to starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, taffy, gum arabic, pregelatinized starch, corn starch, cellulose powder, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, glucose, sorbitol and talc.

[0041] In one aspect of the present disclosure, the composition can be administered to a subject in various forms according to the route of administration of the selection understood by a person of ordinary skill in the relevant art. For example, the composition of the present disclosure can be applied by topical, enteral or parenteral application. Topical application includes, but is not limited to, epidermal application, inhalation, enema, eye drops, ear drops and mucosal application. Enteral application includes oral administration, rectal administration, vaginal administration and gastric feeding tube administration. Parenteral administration includes, but is not limited to, intravenous, intraarterial, intracapsular, intraorbital, intracardiac, intradermal, transtracheal, subcutaneous, intraarticular, subcapsular, subarachnoid, intramedullary, epidural, intrasternal, abdominal, subcutaneous, intramuscular, transepithelial, intranasal, intrapulmonary, intrathecal, rectal and topical administration.

[0042] In addition, in one aspect of the present disclosure, the composition can be formulated into any form suitable for the selected route of administration. For formulation purposes, the composition can be prepared using a diluent or excipient, including but not limited to fillers, bulking agents, binders, wetting agents, disintegrants, surfactants, etc.

[0043] In one aspect of the present disclosure, the composition may include a DNA aptamer of one aspect of the present disclosure, and the effective amount of the DNA aptamer may be determined by a person skilled in the art taking into account the route of administration and the weight, age, gender, health condition, diet, intake time, excretion rate, etc. of the subject in need of administration.

[0044] The DNA aptamers selected and optimized in the present disclosure to obtain high binding affinity to cancer cells can be effectively used in the diagnosis and treatment of cancer due to their enhanced targeting efficiency to target cells and tissues and high serum stability. SEQUENCE LISTING <110> National Cancer Center Zaipeng Biotech Co., Ltd. <120> Novel DNA aptamers and their uses <130> P21116432WP <150> KR10-2018-0167948 <151> 2018-12-21 <160> 17 <170> PatentIn version 3.5 <210> 1 <211> 76 <212> DNA <213> Artificial Sequence <220> <223> DNA library nucleotide design <220> <221> Unsure <222> (19)..(58) <223> DNA library random sequence N19-N58 <220> <221> misc_feature <222> (19)..(58) <223> n is a, c, g, or t <400> 1 ataccagctt attcaattnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnag 60 atagtaagtg caatct 76 <210> 2 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> DNA library forward primer <220> <221> 5'clip <222> (1) <223> Cy5 added to the 5' end <400> 2 ataccagctt attcaatt 18 <210> 3 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> DNA library reverse primer <220> <221> 5'clip <222> (1) <223> Add biotin at the 5' end <400> 3 agattgcact tactatct 18 <210> 4 <211> 80 <212> DNA <213> Artificial Sequence <220> <223> DNA aptamer SQ7 <400> 4 agcagcacag aggtcagatg atgttggtat atacttcttt agcttggaac caactcttgc 60 cctatgcgtg ctaccgtgaa 80 <210> 5 <211> 80 <212> DNA <213> Artificial Sequence <220> <223> DNA aptamer SQ8-Comp <400> 5 agcagcacag aggtcagatg gaacccgata aagaataagt acgacaaggt ggcgagagcc 60 cctatgcgtg ctaccgtgaa 80 <210> 6 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> DNA aptamer SQ7-1 <400> 6 gttggtatat acttctttag cttggaacca ac 32 <210> 7 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> DNA aptamer SQ7-1-Rev <400> 7 caaccatata tgaagaaatc gaaccttggt tg 32 <210> 8 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> Internally 2'-O-methyl modified aptamer SQ7-1(1) <220> <221> modified_base <222> (1)..(6) <223> 2'-O-methyl modified bases (1-6) <400> 8 guugguatat acttctttag cttggaacca ac 32 <210> 9 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> Internally 2'-O-methyl modified aptamer SQ7-1(2) <220> <221> modified_base <222> (7)..(11) <223> 2'-O-methyl modified bases (7-11) <400> 9 gttggtauau acttctttag cttggaacca ac 32 <210> 10 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> Internal 2'-O-methyl modified aptamer SQ7-1(3) <220> <221> modified_base <222> (14)..(18) <223> 2'-O-methyl modified bases (14-18) <400> 10 gttggtatat actucuuuag cttggaacca ac 32 <210> 11 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> Internally 2'-O-methyl modified aptamer SQ7-1(4) <220> <221> modified_base <222> (21)..(26) <223> 2'-O-methyl modified bases (21-26) <400> 11 gttggtatat acttctttag cuuggaacca ac 32 <210> 12 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> Internally 2'-O-methyl modified aptamer SQ7-1(5) <220> <221> modified_base <222> (27)..(32) <223> 2'-O-methyl modified bases (27-32) <400> 12 gttggtatat acttctttag cttggaacca ac 32 <210> 13 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> Internally 2'-O-methyl modified aptamer SQ7-1(6) <220> <221> modified_base <222> (7)..(26) <223> 2'-O-methyl modified bases (7-26) <400> 13 gttggtauau acuucuuuag cuuggaacca ac 32 <210> 14 <211> 32 <212> DNA <213> Artificial Sequence <220> <223> Internal 2'-O-methyl modified aptamer SQ7-1(1,5) <220> <221> modified_base <222> (1)..(6) <223> 2'-O-methyl modified bases (1-6) <220> <221> modified_base <222> (27)..(32) <223> 2'-O-methyl modified bases (27-32) <400> 14 guugguatat acttctttag cttggaacca ac 32 <210> 15 <211> 79 <212> DNA <213> Artificial Sequence <220> <223> DNA aptamer SQ7a <400> 15 agcagcacag aggtcagatg atgttggtat atacttcttt agcttggaac caactcttct 60 cctatgcgtg ctaccgtga 79 <210> 16 <211> 80 <212> DNA <213> Artificial Sequence <220> <223> DNA aptamer SQ7b <400> 16 agcaacacag aggtcagatg atgttggtat atacttcttt agcttggaac ccactcttgt 60 cctatgcgtg ctaccgtgaa 80 <210> 17 <211> 80 <212> DNA <213> Artificial Sequence <220> <223> DNA aptamer SQ1 <400> 17 agcagcacag aggtcagatg cttgggctat ctcttattca tgctgttcca ccgctctcgg 60 cctatgcgtg ctaccgtgaa 80 BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 The design of the nucleotide sequence included in the DNA library of the present disclosure and the design of the forward primer and the reverse primer that can be used to amplify or identify the above-mentioned nucleotide sequence are shown. Specifically, the nucleotide sequence in the DNA library contains 20 fixed nucleotides at the 5' end, 40 random nucleotides in the middle, and another 20 fixed nucleotides at the 3' end. The forward primer is labeled with Cy5 at its 5' end (5'-Cy5-sequence-3'), and the reverse primer is labeled with biotin at its 5' end (5'-biotin-sequence-3').

[0046] Figure 2 Results of enriching a ssDNA pool having binding affinity to pancreatic cancer cells from the DNA library of the present disclosure are shown, and flow cytometry (fluorescence activated cell sorter; FACS) was used to determine whether the cell binding affinity of the pool increased with the number of rounds.

[0047] Figure 3 Schematic diagram of the process of screening aptamers using metastatic pancreatic cancer cells by Cell-SELEX technology in the present disclosure.

[0048] Figure 4 The results of measuring the cell binding affinity of each Cy5-labeled candidate aptamer obtained by screening aptamers using metastatic pancreatic cancer cells by the Cell-SELEX technique in the present disclosure are shown.

[0049] Figure 5 The secondary structure of the SQ7 aptamer obtained by screening aptamers using metastatic pancreatic cancer cells by the Cell-SELEX technique in the present disclosure is described.

[0050] Figure 6a The results of measuring the target cell binding affinity of the SQ7 aptamer disclosed in the present invention using flow cytometry (FACS) are shown. Specifically, the binding of the SQ7 aptamer to target cells was measured, and the no treatment control (NT), DNA pool library and SQ8-Comp aptamer were used as controls.

[0051] Figure 6b The results of measuring the target cell binding affinity of the SQ7-1 aptamer disclosed in the present invention using flow cytometry (FACS) are shown. Specifically, the binding of the SQ7 aptamer and the SQ7-1 aptamer to the target cells was measured, and the no treatment control (NT), the DNA pool library and the SQ8-Comp aptamer were used as controls.

[0052] Figure 7 The secondary structure of the SQ7-1 aptamer prepared based on the SQ7 aptamer of the present disclosure is described.

[0053] Figure 8 The targeting distribution of the SQ7 aptamer of the present disclosure to target cells determined by confocal microscopy is shown. The gray ellipse represents the cell nucleus, and the brightest white area represents the aptamer bound to the cell surface or internalized into the cell.

[0054] Fig. 9 The targeting distribution of the SQ7-1 aptamer of the present disclosure to target cells determined by confocal microscopy is shown. The gray ellipse represents the cell nucleus, and the brightest white area represents the aptamer bound to the cell surface or internalized into the cell.

[0055] Fig.10 The targeting distribution of the SQ7 aptamer of the present disclosure to pancreatic cancer tissues determined by bioluminescence imaging in a xenograft mouse model of a human pancreatic cancer cell line is shown.

[0056] Fig.11 The targeting distribution of the SQ7-1 aptamer of the present disclosure to pancreatic cancer tissues determined by bioluminescence imaging in a xenograft mouse model of a human pancreatic cancer cell line is shown.

[0057] Figures 12a to 12d The secondary structures and modification positions of the SQ7-1(1), SQ7-1(2), SQ7-1(3), SQ7-1(4), SQ7-1(5), SQ7-1(6), and SQ7-1(1,5) aptamers are described, which are internal 2'-O-methyl modified aptamers prepared based on the SQ7-1 aptamer disclosed herein. Fig.12a The region of internal 2'-O-methyl modification is depicted by a rectangle, and Figures 12b to 12d Specifically disclosed is the nucleotide sequence of each region of internal 2'-O-methyl modification.

[0058] Figures 13a to 13d Shown are the determined serum half-lives of the SQ7-1, SQ7-1(1), SQ7-1(5), and SQ7-1(1,5) aptamers of the present disclosure.

[0059] Fig.14 The target cell binding affinities of the SQ7-1, SQ7-1(1), SQ7-1(5) and SQ7-1(1,5) aptamers of the present disclosure measured by flow cytometry are shown.

[0060] Fig.15 The targeted distribution of the SQ7-1 aptamer of the present disclosure to pancreatic cancer tissues determined by bioluminescence imaging in xenograft mouse models of various pancreatic cancer cell lines from human pancreatic cancer patients is shown.

[0061] Fig.16a and Fig.16b The binding affinity of the SQ7-1 aptamer of the present disclosure to various pancreatic cancer cell lines determined by flow cytometry (FACS) is shown.

[0062] Fig.17 The geometric mean (expressed as a fold) of the relative fluorescence intensity of the SQ7-1 aptamer relative to the SQ7-1-Rev aptamer based on the results obtained in FIG. 16 is shown.

[0063] Fig.18 Shown are the geometric means of the relative fluorescence intensities of the SQ7-1 aptamer relative to the SQ7-1-Rev aptamer (expressed as folds), based on the binding affinities of the SQ7-1 aptamers of the present disclosure to various cancer cell lines determined by flow cytometry (FACS).

[0064] Fig.19 Shown are the geometric means of the relative fluorescence intensities of the SQ7-1 aptamer relative to the SQ7-1-Rev aptamer (expressed as folds), based on the binding affinities of the SQ7-1 aptamers of the present disclosure to various pancreatic cancer PDOX-derived cell lines determined by flow cytometry (FACS). DETAILED DESCRIPTION OF THE INVENTION

[0066] The present disclosure can be clearly understood from the above-mentioned various aspects and one or more experimental embodiments described below. Hereinafter, the present disclosure will be explained in detail so that those of ordinary skill in the art can easily understand and reproduce the present disclosure by referring to the working examples described in the accompanying tables. However, the experimental examples or embodiments given below are only used to illustrate the present disclosure, and the scope of the present disclosure is not limited to such experimental examples or embodiments.

[0067] [Experimental Example 1] Screening of aptamers using Cell-SELEX

[0068] The experimental procedure for screening aptamers that specifically bind to pancreatic cancer cells using Cell-SELEX technology is as follows Figure 3 shown.

[0069] Specifically, in order to obtain a cell line expressing cell membrane proteins (a characteristic of pancreatic cancer), pancreatic cancer cells were transplanted into animal models, and the pancreatic cancer cell line CMLu-1 ( Figure 3 A).

[0070] The ssDNA library was prepared and then screened using the pancreatic cancer cell line CMLu-1 cells as target cells (positive cells) and hTERT / HPNE cells (human pancreatic nestin-expressing cells) as control cells (negative cells). Multiple rounds of repeated selection of ssDNA molecules that only bind to pancreatic cancer cells but not to control cells were performed, and the resulting enriched ssDNA pool was cloned and sequenced, followed by clustering.

[0071] (1) Establishment of metastatic pancreatic cancer cell lines from xenograft mouse models of human pancreatic cancer cell lines

[0072] The method for obtaining the metastatic pancreatic cancer cell line CMLu-1 is described as follows. An orthotopic mouse model was established using NOD / SCID mice. First, in order to construct an animal model capable of simulating pancreatic cancer metastasis, a pancreatic cancer cell line stably expressing firefly luciferase (CFPAC-1-Luci) was established and used to non-invasively monitor tumor occurrence over time. CFPAC-1-Luci pancreatic cancer cells were orthotopically transplanted into NOD / SCID mice. After 43 days, tumor tissue was removed from the lung tissue of mice with pancreatic cancer metastasis, and the isolated tumor tissue was genotyped, indicating that the genetic properties of metastatic tumor cells were the same as those of pancreatic cancer cells. Then, single cells were prepared from the tumor tissue and cultured. CMLu-1 cells isolated from metastatic tumor tissues were cultured and maintained in RPMI-1640 medium (Hyclone, Logan, UT, USA) plus 10% FBS (Thermo Fisher Scientific, USA) and 100 IU / mL of antibiotic-antimycotic (Gibco).

[0073] The obtained CMLu-1 cells were used as positively selected cells in Cell-SELEX, and human pancreatic duct normal epithelial cells (HPNE) purchased from ATCC Inc. were used as negatively selected control cells.

[0074] (2) Preparation of ssDNA library and primers for Cell-SELEX

[0075] The DNA library for pancreatic cancer-specific aptamers in Cell-SELEX is a pool of DNA sequences composed of fixed and specific nucleotide combinations. The DNA sequence includes 20 fixed nucleotides at the 5' end, 40 random nucleotides in the middle, and 20 fixed nucleotides at the 3' end. The 5' end of the DNA sequence is labeled with Cy5 to monitor the enrichment of the selection using a fluorescence activated cell sorter ("FACS", i.e. "flow cytometer"), and the 3' end is labeled with biotin to purify the ssDNA molecules ( Figure 1 ). In addition, the forward primer was labeled with Cy5 at its 5'-end (5'-Cy5-sequence-3'), and the reverse primer was labeled with biotin at its 5'-end (5'-biotin-sequence-3'). The DNA composition in the DNA library and the forward primer and reverse primer are shown in Table 1.

[0076] [Table 1]

[0077]

[0078] PCR was used to amplify the eluted DNA pool. ssDNA was isolated by capturing the biotinylated complementary strand using streptavidin-biotin bonds and denaturing double-stranded DNA with NaOH. PCR mixtures were prepared and PCR was performed according to the supplier's instructions.

[0079] (3) Screening the library by Cell-SELEX

[0080] Using CMLu-1 cells as target cells (positive cells) and hTERT / HPNE cells as control cells (negative cells), the ssDNA library prepared as described above was screened. 10 nmol of the DNA library was dissolved in 1000 μL of binding buffer (Dulbecco's PBS (Hyclone, USA) containing 5 mM MgCl2, 0.1 mg / mL tRNA, and 1 mg / mL BSA). The DNA library or enriched pool was denatured at 95°C for 10 min, cooled on ice for 10 min, and then incubated with CMLu-1 cells on an orbital shaker at 4°C for 1 hour.

[0081] The CMLu-1 cells were then washed three times to remove unbound DNA sequences, and the bound DNA molecules were eluted by centrifugation at 95°C for 15 min using 1000 μL of binding buffer. For counter-selection, the aptamer pool was incubated with hTERT / HPNE cells for 1 hour, and the supernatant was collected for negative selection. The enriched pool was monitored using FACS and cloned into Escherichia coli using Quiagen's cloning sequencing kit (Quiagen, Germany) to identify candidate aptamers.

[0082] (4) Cloning and sequencing of the enriched ssDNA pool and multiple sequence alignment

[0083] To select candidate sequences, the ssDNA pools enriched in five rounds were cloned and sequenced. The ssDNA pools were amplified by PCR using unmodified primers, ligated into the pGEM-T easy vector (Promega, USA), and then cloned into the HIT TM -DH5α competent cells (Promega, USA). Thereafter, the sequences of 200 clones were analyzed using Cosmogenetech Inc. (Seoul, Korea) and aligned using ClustalX 1.83.

[0084] The degree of enrichment according to the number of selection rounds is as follows Figure 2 shown.

[0085] The process described in (1) to (4) above is as follows Figure 3As shown. The aptamers sequenced by the above process were clustered and divided into aptamers with similar sequences. Finally, 11 Cy5-labeled candidate aptamer families (SQ1 to SQ11) were identified. The content of a single aptamer family in the entire pool is shown in Table 2 below.

[0086] [Table 2]

[0087]

[0088]

[0089] [Experimental Example 2] Determination of the specificity of the enriched candidate aptamer family binding to target cells

[0090] The enriched candidate aptamer family obtained in (4) of Experimental Example 1 was measured for its specificity in binding to CMLu-1 target cells using flow cytometry (FACS).

[0091] Each Cy5-labeled candidate aptamer family was mixed with 3×10 5 CMLu-1 cells and hTERT / HPNE cells were incubated together in Cell-SELEX binding buffer at 4°C for 1 hour. The cells were washed three times with binding buffer containing 0.1% NaN3, and the cells with the sequence bound were resuspended in binding buffer. BD Facscalibur TM and FACSVerse TM (BD Biosciences, USA) was used to detect fluorescence of 10,000 cells, and the data were analyzed using FlowJov10.0.7 software.

[0092] Figure 4 Results of determining the target cell binding affinity of a family of candidate Cy5-labeled aptamers are shown. The aptamer with the highest binding specificity to metastatic pancreatic cancer cells (CMLu-1), the target cell, was identified as SQ7, the sequence of which is shown below.

[0093] *SQ7 aptamer sequence

[0094] 5'-AGCAGCACAGAGGTCAGATGATGTTGGGTATATACTTCTTTAGCTTGGAACCAACTCTTGCCCTATGCGTGCTACCGTGAA-3'(SEQ ID NO:4)

[0095] The following table lists the aptamer sequences included in the SQ7 family.

[0096] [Table 3] Sequences of SQ7 and SQ7 subtypes

[0097]

[0098] [Experimental Example 3] Analysis of SQ7 aptamers and functional identification of aptamer fragments

[0099] The secondary structure of the SQ7 aptamer selected in Experimental Example 2 was determined as follows: Figure 5 As shown. In addition, in order to confirm the cell binding affinity, the SQ7 aptamer, as well as the untreated control (NT), the DNA pool library, and the SQ8-Comp aptamer (an aptamer having a nucleotide sequence partially complementary to the SQ8 aptamer; SEQ ID NO: 5) as controls, were assayed for target cell binding using FACS in the same manner as in Experimental Example 2. As shown in FIG6 , the results indicate that, although the control groups (i.e., NT, the DNA pool library, and the SQ8-Comp aptamer) all exhibited similar low levels of binding affinity, the SQ7 aptamer exhibited significantly superior target cell binding affinity.

[0100] In order to determine whether certain parts of the SQ7 aptamer are critical for pancreatic cancer-specific binding, various aptamers containing parts of the SQ7 aptamer were prepared and their binding affinities to target cells were studied. If the length of the aptamer can be shortened while maintaining its cell binding affinity, it is likely to reduce the production cost of the aptamer while enhancing cell penetration. The results show that the SQ7-1 aptamer having the sequence shown in Table 4 below has advantages in endocytosis while almost completely retaining its binding affinity to target cells. In view of the above results, the target cell binding affinities of the SQ7 aptamer, SQ7-1 aptamer, NT, DNA pool library and SQ8-Comp aptamer were determined using FACS in the same manner as in Experimental Example 2. As Figure 6b As shown, the results indicate that the control groups (i.e., NT, DNA library, and SQ8-Comp aptamers) had similar levels of low binding affinity, whereas the SQ7-1 aptamer, like the SQ7 aptamer, exhibited significantly superior target cell binding affinity.

[0101] The nucleotide sequence of the SQ7-1 aptamer is shown in the following table (SEQ ID NO: 6), and the corresponding secondary structure is shown in Figure 7 In addition, SQ7-1-Rev aptamer (an aptamer having a sequence in the opposite direction of SQ7-1; SEQ ID NO: 7) was prepared so that it could be used as a control for SQ7-1 aptamer in subsequent experiments.

[0102] [Table 4]

[0103]

[0104] [Experimental Example 4] Determination of the efficiency of selected aptamers in targeting cells and tissues

[0105] (1) Determine the endocytosis efficiency of the selected aptamers by confocal microscopy imaging.

[0106] 4 hours before the experiment, 1×10 4 Cells / well control cells (HPNE) and target cells (CMLu-1) were plated on 8-well chamber slides (Thermo scientific, USA) coated with poly-L-lysine (Sigma, USA). After washing with washing buffer, Cy5-labeled aptamers (250nM) or DNA pool libraries were added and incubated at 4°C in 200μL binding buffer. After washing twice, the cells were fixed with 4% paraformaldehyde and then the nuclei were stained with Hoechst33342. Afterwards, the cells were imaged by confocal microscopy (LSM780, Carl Zeiss, Germany), and the images obtained were analyzed with the software Zen blue edition.

[0107] Confocal microscopy results of SQ7 and SQ7-1 aptamers are shown in Figure 8 and 9 As shown in the figure, the brightest white area represents the area with dense aptamers. Figure 8 and 9 As shown, SQ7 and SQ7-1 aptamers targeted pancreatic cancer cells but not control cells and exhibited good cellular endocytosis (internalization) levels.

[0108] (2) Determination of aptamer targeting pancreatic cancer by in vivo and in vitro fluorescence imaging

[0109] Female Hsd:Athymic nude-Foxn1 nude mice aged 6 weeks were purchased from Harlan Laboratories, Inc, France. Mice were housed in a specific pathogen free (SPF) environment under controlled light and humidity conditions, and food and water were provided by the NCC animal facility. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the National Cancer Center Research Institute (NCCRI) (NCC-16-247). NCCRI is an institution accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).

[0110] CFPAC-1 cells (1 × 10 6 The orthotopic xenograft mouse model of pancreatic cancer was constructed by injecting 500 cells into the tail of the pancreas of mice. Three weeks after inoculation, the mice were divided into two groups according to the treatment method (Cy5.5-SQ8-Comp aptamer vs Cy5.5-SQ7 aptamer or Cy5.5-SQ7-1-Rev aptamer vs Cy5.5-SQ7-1 aptamer), and then intravenously administered the above Cy5.5-labeled aptamer (300 pmol / 50 μL PBS).

[0111] For in vitro experiments, mice were sacrificed 15 minutes or 3 hours after administration and then dissected. Tumor tissues were isolated and bioluminescent images were performed using IVIS Lumina (Caliper Life Science, Hopkinton, MA, USA). All image data were analyzed using the software Living Image Acquisition and Analysis.

[0112] Fig.10 and 11 The grayscale images in Figure 2 show the bioluminescence imaging results of SQ7 and SQ7-1 aptamers. The total flux obtained from the imaging results is plotted in Fig.10 and 11 middle.

[0113] In the imaging results shown at the top of the above figure, the brighter (whiter) the area, the greater the number of aptamers bound to the cells in that area. It can be seen that the imaging results of the SQ7 and SQ7-1 aptamers are whiter than those of the other aptamers.

[0114] Therefore, it can be shown that the aptamer of the present disclosure moves to and specifically binds to pancreatic cancer tissues and has significantly superior targeting efficiency to pancreatic cancer tissues compared to other control aptamers (SQ1 aptamer (SEQ ID NO: 17), SQ8-Comp aptamer, and SQ7-1-Rev aptamer).

[0115] [Experimental Example 5] Preparation and identification of modified aptamers with enhanced serum stability

[0116] Based on the SQ7-1 aptamer prepared in the above experimental example, an internal 2'-O-methyl modified aptamer was prepared to enhance the serum stability of the aptamer. Specifically, SQ7-1(1), SQ7-1(2), SQ7-1(3), SQ7-1(4), SQ7-1(5), SQ7-1(6) and SQ7-1(1,5) aptamers were prepared by modifying different regions in the secondary structure of the SQ7-1 aptamer. Figures 12a to 12d ).

[0117] The nucleotide sequences of the generated internal 2'-O-methyl modified aptamers are summarized in Table 5 below.

[0118] [Table 5]

[0119]

[0120]

[0121] 5 μg of each internal 2'-O-methyl modified aptamer prepared above was incubated in mouse serum at 37°C for 0, 0.1, 0.5, 2, 6 and 24 hours. At each time point, 0.5 M EDTA was added to the sample to inhibit DNase activity, and then EtOH-NaOAc was added to achieve precipitation. The DNA aptamer precipitation samples were analyzed by HPLC.

[0122] Chromatography was performed using a Waters e2695 HPLC system (MA, USA) equipped with a variable wavelength detector (VWD) QuatPump. Chromatographic data were processed using a personal computer equipped with Empower3 personal single system software for LC. Analytes were separated using a Venusil, XBP C18 column (250 mm × 4.6 mm, 5 μm) purchased from Agela Technologies Inc. (Beijing, China). The mobile phase was a mixture of methanol-water (55:45, volume ratio) at a flow rate of 0.5 mL / min. The column temperature was 30 ° C and the measurement wavelength was 260 nm. A 15 μL LC micro-syringe purchased from Shanghai GaoGe Industrial and Trading Co., Ltd. (Shanghai, China) was used for injection.

[0123] The results showed that the SQ7-1(1), SQ7-1(5) and SQ7-1(1,5) aptamers had significantly increased half-lives. Specifically, as shown in Figure 13, the half-lives of the SQ7-1(1), SQ7-1(5) and SQ7-1(1,5) aptamers increased by 91 times, 145 times and 760 times, respectively, relative to the SQ7-1 aptamer. Compared with the SQ7-1 aptamer, the binding affinity of the above aptamers to target cells was slightly lower, but still significantly higher than that of the aptamers in the DNA pool library (the thin solid line on the far left of the figure) ( Fig.14 ).

[0124] In summary, as described above, the DNA aptamers of the present disclosure specifically bind to pancreatic cancer with high binding affinity. It has been shown that the targeting efficiency of target cells or tissues can be increased by reducing the size of the selected aptamers, and serum stability can be increased by modifications that enhance resistance to DNA enzymes.

[0125] [Experimental Example 6] Human pancreatic cancer tissue (Patient-Derived Orthotopic Xenograft Model; PDOX Model) Targeting Determination

[0126] To determine whether the aptamers of the present disclosure also exhibit excellent targeting efficiency in a PDOX model that can reproduce the complexity and heterogeneity of patient tumor tissues, in vivo validation experiments were performed using fluorescence imaging.

[0127] With the approval of the NCC Institutional Review Board ("IRB"), samples were collected from patients who submitted informed consent and transplanted directly into the pancreas of nude mice (purchased from Harlan Laboratories, Inc. (France)) to establish a patient-derived orthotopic xenograft (PDOX) model. For primary tumor samples (hereinafter referred to as "HPT") from patients with pancreatic cancer, direct surgical resection was performed; for patients with advanced pancreatic cancer who could not undergo surgery, after collecting liver metastasis tissue biopsy samples (hereinafter referred to as "GUN") from patients, the samples were transferred to a test tube containing culture medium and transplanted into female Hsd: Athymic nude-Foxn1 nude mice (obtained from the same source as in Experimental Example 4) as soon as possible by making an incision in the tail of the pancreas and closing the incision after transplantation (first generation PDOX, F1). Thereafter, tumor size was measured regularly by abdominal palpation and MRI, and when the tumor volume reached 3000mm 3 When the tumor tissue is obtained, the mice are killed. Then, tumor tissue fragments of a certain size (3mm*3mm*3mm) are re-implanted orthotopically into multiple nude mouse subjects to produce offspring (F2, F3, F4...) and increase the number of subjects.

[0128] At the 4th generation (F4), the established PDOX mouse model was divided into two groups, each with three subjects, and the SQ7-1 aptamer or SQ7-1-Rev aptamer (300 pmol / 50 μL PBS) was injected intravenously in the form of Cy5.5-labeled aptamers. After 15 minutes of administration, the mice were killed and dissected, the tumor tissue was removed, and then bioluminescence imaging was performed using IVIS Lumina (Caliper Life Science, Hopkinton, MA, USA). All image data were analyzed using the software Living Image Acquisition and Analysis. Fig.15 The grayscale image in Figure 2 shows the results of bioluminescence imaging. The total flux obtained from the imaging results is shown in Figure 2. Fig.15 shown.

[0129] and Fig.10 and 11 Same, in Fig.15 In the imaging results shown at the top, the brighter (whiter) the area, the greater the number of aptamers bound to the cells in that area. It can be seen that the image of the SQ7-1 aptamer is whiter than that of the SQ7-1-Rev aptamer.

[0130] Therefore, it was demonstrated that the aptamers of the present disclosure had significantly superior targeting efficiency even in the PDOX model that retains the complexity and heterogeneity of patient tumor tissues.

[0131] [Experimental Example 7] Determination of Binding Affinity of Different Pancreatic Cancer Cell Lines

[0132] Additional flow cytometry (FACS) analysis was performed to determine the binding affinity of the aptamers of the present disclosure to various pancreatic cancer cell lines.

[0133] [Preparation of antibody-binding aptamers]

[0134] 250 nM digoxigenin-labeled SQ7-1 aptamer and 125 nM anti-digoxigenin antibody (Abcam; Cat. No. ab420, USA) were mixed at room temperature for 30 minutes to prepare an antibody-binding aptamer.

[0135] Flow cytometric analysis was performed in the same manner as in Experimental Example 2, except that the antibody-binding aptamer prepared as described above was used, and Alexa 488-labeled anti-mouse IgG (Invitrogen, USA) was used as the secondary antibody at a concentration of 4 μg / mL. Cells from CFPAC-1 cell line, SNU-213 cell line, SNU-410 cell line, Capan-2 cell line, HPAF-II cell line, AsPC-1 cell line, Capan-1 cell line, MIA PaCa cell line, BxPC-3 cell line, and PANC-1 cell line were used. All of the above cell lines were purchased from ATCC.

[0136] The results of determining the binding affinity of the aptamers to various pancreatic cancer cell lines are shown in FIGS. 16 and 17 . Fig.17 The geometric mean (expressed as fold) of the relative fluorescence intensity of the SQ7-1 aptamer relative to the SQ7-1-Rev aptamer is shown.

[0137] According to the results shown in Figures 16 and 17, the SQ7-1 aptamer of the present disclosure more effectively and specifically binds to all pancreatic cancer cell lines compared to the SQ7-1-Rev aptamer. Combined with the results of Experimental Examples 4 and 6 discussed above, it can be seen that the aptamer of the present disclosure can specifically bind to various types of pancreatic cancer cells.

[0138] Furthermore, the SQ7 aptamer was able to similarly specifically bind to various types of pancreatic cancer cells because it contained the SQ7-1 aptamer sequence.

[0139] [Experimental Example 8] Determination of binding affinity of various tumor cell lines

[0140] Additional flow cytometry (FACS) analysis was performed to determine the binding affinity of the aptamers of the present disclosure to various tumor cell lines.

[0141] Flow cytometry analysis was performed in the same manner as in Experimental Example 2, but using the same antibody-binding aptamer and secondary antibody as in Experimental Example 7. Cells from U87 cell line, U251 cell line, CAL27 cell line, HEP3B cell line, A549 cell line, HCT116 cell line, SK-OV3 cell line, ES-2 cell line, MCF7 cell line, SK-BR3 cell line, NCI-N87 cell line, KPL4 cell line, BT-474 cell line, MDA-MB231 cell line, and HCC1938 cell line were used. All of the above cell lines were purchased from ATCC.

[0142] The results of the determination of the binding affinity of the aptamer to various cancer cell lines are shown in Fig.18 shown. Fig.18 The geometric mean (in fold) of the relative fluorescence intensity of the SQ7-1 aptamer and the SQ7-1-Rev aptamer is shown.

[0143] according to Fig.18 The results shown show that the SQ7-1 aptamer of the present disclosure binds more effectively and specifically to various cancer cell lines, such as colon cancer, liver cancer, lung cancer, brain tumor, oral cancer, ovarian cancer and breast cancer cell lines, compared to the SQ7-1-Rev aptamer. Combined with the results of Experimental Examples 4 and 6 discussed above, it can be seen that the aptamer of the present disclosure can specifically bind to various types of cancer cells.

[0144] In addition, the SQ7 aptamer also specifically binds to various types of cancer cells because it contains the SQ7-1 aptamer sequence.

[0145] [Experimental Example 9] Determination of Binding Affinity of Pancreatic Ductal Adenocarcinoma PDOX-Derived Cell Lines

[0146] Additional flow cytometry (FACS) analysis was performed to determine whether the aptamers of the present disclosure could specifically bind to pancreatic cancer cells from clinical patients.

[0147] Unlike normal cells that have only a limited number of cell divisions before death, cancer cells have the characteristic of unlimited division. Therefore, cancer cells isolated from tumor tissues are believed to be able to form cell lines that can proliferate indefinitely even in the absence of transfection and reproduce the clinical and molecular biological characteristics of patients. In this experiment, tumor tissue removed from pancreatic cancer PDOX mice was divided into 3mm×4mm fragments, mixed with a human cell dissociation kit containing collagenase (MiltenyiBiotech Inc.), and placed in a tissue dissociator (Gentle Macs, Miltenyi Biotech Inc) for 1 hour to separate cells from connective tissue. After the reaction is complete, RPMI medium containing fetal bovine serum (FBS) is added to inhibit enzyme activity, followed by centrifugation to obtain a cell precipitate dissociated from the tissue. The precipitate was suspended in RPMI medium containing FBS, and the cells were then evenly plated on a 10cm culture dish to 2×10 6 The culture medium was changed every other day, while normal fibroblasts and dead cells were removed, thereby establishing a PDOX-derived cancer cell line for each pancreatic cancer patient. The established cell lines were named in the same way as the PDOX from which they were derived.

[0148] The cancer cell lines isolated from tumor tissues of the PDOX model using biopsy tissues of patients with liver metastasis (GUN#13, GUN#16, GUN#20, GUN#34, GUN#38, GUN#41 and GUN#46), the cancer cell lines isolated from tumor tissues of the PDOX model using endoscopic ultrasound-guided fine needle biopsy samples (EUS#16), and the cancer cell lines isolated from tumor tissues of the PDOX model using surgical resection samples (HPT#19, HPT#22, HPT#43, HPT#45 and HPT#48) were subjected to flow cytometry analysis in the same manner as in Experimental Example 2, except that the same antibody-binding aptamer as in Experimental Example 7 was used.

[0149] The results of determining the binding affinity of the aptamers to various PDOX-derived cell lines are shown in Fig.19 middle. Fig.19 The geometric mean (in fold) of the relative fluorescence intensity of the SQ7-1 aptamer and the SQ7-1-Rev aptamer is shown.

[0150] according to Fig.19The results shown in Figure 2 show that, compared with the SQ7-1-Rev aptamer, the SQ7-1 aptamer of the present disclosure binds more effectively and specifically to various PDOX-derived cell lines, which are derived from pancreatic cancer tissues collected from different patients. Combined with the results of Experimental Examples 4 and 6 discussed above, it can be seen that the aptamer of the present disclosure is able to specifically bind to pancreatic cancer tissues of clinical patients.

[0151] In addition, the SQ7 aptamer also specifically binds to the patient's pancreatic cancer tissue because it contains the SQ7-1 aptamer sequence.

[0152] Although the technical concept of the present disclosure has been described above by referring to the embodiments provided in the working examples and illustrated in the drawings, it should be noted that various substitutions, modifications and changes can be made without departing from the technical concept and scope of the present disclosure that can be understood by a person of ordinary skill in the art to which the present disclosure belongs. In addition, it should be noted that such substitutions, modifications and changes are included in the scope of the appended claims.

Claims

1. A DNA aptamer, consisting of the nucleotide sequence shown in SEQ ID NO:

6.

2. The DNA aptamer according to claim 1, wherein The aptamer has been modified to be resistant to DNase; The modification is to replace the -OH group on the 2' carbon of the sugar group in one or more nucleotides with -Me (methyl), -OMe, -NH2, -F (fluorine), -O-2-methoxyethyl-O-propyl, -O-2-methylthioethyl, -O-3-aminopropyl, -O-3-dimethylaminopropyl, -ON-methylacetamido or -O-dimethylamidooxyethyl.

3. The DNA aptamer according to claim 2, wherein The modification is present in at least 10% of the nucleotides of SEQ ID NO:

6.

4. The DNA aptamer according to claim 2, wherein The DNA aptamer has a nucleotide sequence as shown in SEQ ID NO: 8, 12 or 14.

5. A DNA aptamer, which consists of the nucleotide sequence shown in SEQ ID NO:

4.

6. A composition for targeting cancer tissue or for diagnosing cancer, the composition comprising the DNA aptamer according to any one of claims 1 to 5.

7. Use of the DNA aptamer according to any one of claims 1 to 5 in preparing a composition for treating cancer; The cancer is pancreatic cancer, colon cancer, liver cancer, lung cancer, brain tumor, oral cancer, ovarian cancer or breast cancer.

8. The use according to claim 7, wherein the composition further comprises an anticancer agent coupled to the DNA aptamer.

9. The use according to claim 8, wherein: The anticancer agent is selected from one or more of the group consisting of MMAE (monomethyl auristatin E), MMAF (monomethyl auristatin F), calicheamicin, mertansine, ravtansine, tesirine, doxorubicin, cisplatin, SN-38, duocarmycin and pyrrolobenzodiazepine.

10. The use according to claim 7, wherein: The DNA aptamer is coupled with polyethylene glycol (PEG), diacylglycerol (DAG), dendrimer, antibody or polymer containing phosphorylcholine.

Citation Information

Patent Citations

  • PAUF-specific aptamer and therapeutic composition for treatment of pancreatic cancer comprising thereof

    KR101250557B1

  • Interleukin-8 aptamers and uses thereof

    KR101458947B1

  • Humanized antibodies against digoxigenin and uses thereof

    CN116157419A

  • Nucleic acid aptamer specifically binding to pancreatic cancer cells or tissues and use thereof

    EP2481800A2

  • Nucleic acid aptamers that can specifically bind to pancreatic cancer cells or tissues and their applications

    JP2012528587A